ANPCYANGLE plc

About ANGLE plc (ANPCY)

ANGLE plc (ANPCY) is a Diagnostics & Research company headquartered in Surrey, ENG, United Kingdom whose shares trade over-the-counter on the OTCQX tier.

ANGLE is a world leading liquid biopsy company with pioneering products and services in cancer diagnostics. ANGLE's lead product is the Parsortix cell separation system, which captures very rare cells from blood including circulating tumour cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The resulting liquid biopsy (simple blood test) enables the investigation of mutations in the patient's cancer for personalised cancer care. ANGLE sells instruments and cassettes for RUO only worldwide and also sells IVD product for use in metastatic breast cancer (MBC) - the Parsortix PC1 Clinical System is FDA cleared for its intended use in MBC and is the first and only FDA cleared medical device to harvest intact CTCs from blood. ANGLE completed an FDA Class II De Novo process. ANGLE has a clinical laboratory in the UK and sells services to pharma for biomarker assay development and clinical trials support by processing blood samples and looking for the biomarker response to a drug. CTCs offer a unique insight as the whole cell can be analysed for DNA, RNA and protein information, clusters can be analysed etc. CTCs have many advantages over both tissue biopsy (one-off and expensive) and also other liquid biopsy analytes (ctDNA limited to DNA alone).

Products and services

Products: Parsortix PR1 (Research Use Only) Instrument and cassettes for the harvesting of circulating tumor cells. Parsortix PC1 (Clinical) for the harvesting of CTCs in metastatic breast cancer - the end user is responsible for the validation of any downstream assay. Services - Pharma services utilising the Parsortix system to help pharma with assay development, clinical trials etc - CTCs are intact living cancer cells and therefore allow DNA, RNA, protein and morphological analysis.

ANPCY key facts

Ticker symbol

ANPCY

Market tier

OTCQX

Sector

Healthcare

Industry

Diagnostics & Research

Headquarters

Surrey, ENG, United Kingdom

Country of incorporation

GB

Year of incorporation

2004

Employees

110

Estimated market cap

$31.98M (as of Apr 9, 2025)

Shares outstanding

322,641,668

Reporting standard

International Reporting: LSE - London Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Semi-Annual Report (Jun 30, 2024)

ANGLE plc leadership

• Andrew Newland — CEO
• Ian F Griffiths — CFO

Explore more: Diagnostics & Research stocks · Healthcare sector · OTCQX stocks · OTC stocks starting with A